This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edmiston, C. E.
Right arrow Articles by Towne, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edmiston, C. E.
Right arrow Articles by Towne, J. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 1012-1016, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1012-1016.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot Infections

Charles E. Edmiston,1* Candace J. Krepel,1 Gary R. Seabrook,1 Lewis R. Somberg,2 Atilla Nakeeb,3 Robert A. Cambria,1 and Jonathan B. Towne1

Divisions of Vascular Surgery,1 Trauma and Critical Care,2 Pancreatobiliary Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin3

Received 2 July 2003/ Returned for modification 24 August 2003/ Accepted 12 November 2003

The in vitro activities of moxifloxacin, ciprofloxacin, levofloxacin, gatifloxacin, imipenem, piperacillin-tazobactam, clindamycin, and metronidazole against 900 surgical isolates were determined using NCCLS testing methods. Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections.

* Corresponding author. Mailing address: Department of Surgery, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226. Phone: (414) 805-5739. Fax: (414) 805-0152. E-mail: edmiston{at}mcw.edu.

Antimicrobial Agents and Chemotherapy, March 2004, p. 1012-1016, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.1012-1016.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ober, M. C., Hoppe-Tichy, T., Koninger, J., Schunter, O., Sonntag, H.-G., Weigand, M. A., Encke, J., Gutt, C., Swoboda, S. (2009). Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother 64: 1091-1095 [Abstract] [Full Text]  
  • Skalioti, C., Tsaganos, T., Stamatiadis, D., Giamarellos-Bourboulis, E. J., Boletis, J., Kanellakopoulou, K. (2009). PHARMACOKINETICS OF MOXIFLOXACIN IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. pdi 29: 575-579 [Abstract] [Full Text]  
  • Lipsky, B. A., Giordano, P., Choudhri, S., Song, J. (2007). Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 60: 370-376 [Abstract] [Full Text]  
  • Stass, H., Rink, A. D., Delesen, H., Kubitza, D., Vestweber, K.-H. (2006). Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 58: 693-696 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Warren, Y. A., Tyrrell, K. L., Merriam, C. V., Fernandez, H. (2006). In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections. Antimicrob. Agents Chemother. 50: 148-155 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Sprandel, K. A., Rodvold, K. A., Rotschafer, J. C. (2005). Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 49: 685-689 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»